A randomized clinical trial of the tracheal tube with subglottic secretion drainage for preventing ventilator-associated pneumonia (VAP).

A randomized clinical trial of the tracheal tube with subglottic secretion drainage for preventing ventilator-associated pneumonia (VAP). - Comparison between VAP incidence by the two types of tracheal tube with subglottic secretion drainage.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003371

Enrollment

240

Registered

2010-04-01

Start date

2010-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ventilator-associated pneumonia (VAP)

Interventions

The use of the tracheal tube with subgosttic secretion drainage (Type1:Hi-Lo Evac&amp

reg) The use of the tracheal tube with subgosttic secretion drainage(Type2:Taper Guard Evac&amp

reg)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patients who are intubated and expected to receive mechanical ventilation at least 72 hours in the ICU.

Exclusion criteria

Exclusion criteria: 1) Patients who are transferred from another hospital and received mechanical ventilation. 2) Patients who received tracheostomy within 72 hours from admission. 3) Patients that it was judged that nasal intubation was necessary 4) Patients who are less than 18 years old. 5) Patients who judged that a medical attendant was inappropriate.

Design outcomes

Primary

Measure	Time frame
VAP incidence Episodes of VAP/1000 ventilator days	—

Secondary

Measure	Time frame
Twenty eight days mortality, Hospital mortality, Duration of mechanical ventilation, Length of ICU stay, Length of hospital stay, The days from an entry to the VAP onset, Cost effectiveness.	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026